Sigyn Therapeutics, Inc.

Overview

Compare with Microbot Medical Inc., Profusa, Inc. or Glucotrack, Inc., or pick any stock.

• TickerSIGY on OTC¹
• IndustrySurgical & Medical Instruments & Apparatus¹
• HeadquartersBeverly Hills, California¹
• Incorporated inDE²
• Business address9190 W Olympic Blvd # 263, Beverly Hills, Ca 90212²
• Filer categoryNon-accelerated filer, Smaller reporting company²

See how the biggest companies compare on our leaderboards

Sigyn Therapy TM as a novel strategy to address several unmet needs in global health:³ From its latest annual report

Corporate structure

Sigyn Therapeutics, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Sigyn Therapeutics, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Investments

Intangibles and goodwill

Inventory

Properties, in its own words

Our corporate address is 2468 Historic Decatur Road, Suite 140, San Diego, California, 92106.

We believe that our existing facilities are adequate for our current needs and that we will be able to lease suitable additional or alternative space on commercially reasonable terms if and when we need it.

Item 2 of the 10-K filed Apr 15, 2025.³

Leadership

Who has led Sigyn Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

• Chief executive officerJoseph Segelman Jan 27, 2016 to Jun 27, 2017¹¹
• PresidentJoseph Segelman Jan 27, 2016 to Jan 27, 2016¹¹

Former names

• Reign Resources CorpMay 15, 2020 to Oct 23, 2020²
• Reign Sapphire CorpMay 27, 2015 to May 12, 2020²

Timeline

1. Feb 20, 20268-K Entered a material agreement; Unregistered sale of shares¹³
2. Aug 15, 20258-K Entered a material agreement; Unregistered sale of shares; Executive or director change¹⁴
3. Mar 7, 20258-K Executive or director change; Regulation FD disclosure¹⁵
4. Jan 16, 20258-K Executive or director change¹⁶
5. Jan 6, 20258-K Bylaws or fiscal year changed¹⁷
6. Oct 16, 20248-K Unregistered sale of shares¹⁸
7. Oct 16, 20248-K Unregistered sale of shares¹⁹
8. Oct 7, 20248-K Unregistered sale of shares²⁰
9. Jun 6, 20248-K Other events²¹
10. May 15, 20248-K Other events²²
11. Apr 16, 20248-K Entered a material agreement²³
12. Jan 31, 20248-K Other events²⁴
13. Jan 27, 2016New chief executive Joseph Segelman becomes CEO¹¹

Filings

64 filings to the SEC since October 2021: 4 annual reports, 13 quarterly reports, 27 major events, 4 large holders, 16 other. The latest 20:

1. Jul 16, 202615-12G EDGAR
2. Mar 31, 2026NT 10-K EDGAR
3. Feb 20, 20268-K EDGAR
4. Jan 14, 2026SCHEDULE 13G/A EDGAR
5. Nov 14, 202510-Q EDGAR
6. Sep 5, 202510-Q EDGAR
7. Aug 15, 20258-K EDGAR
8. Aug 15, 2025NT 10-Q EDGAR
9. May 20, 202510-Q EDGAR
10. May 15, 2025NT 10-Q EDGAR
11. Apr 15, 202510-K EDGAR
12. Mar 31, 2025NT 10-K EDGAR
13. Mar 7, 20258-K EDGAR
14. Feb 14, 2025SCHEDULE 13G/A EDGAR
15. Jan 16, 20258-K EDGAR
16. Jan 6, 20258-K EDGAR
17. Nov 19, 202410-Q EDGAR
18. Nov 15, 2024NT 10-Q EDGAR
19. Oct 16, 20248-K EDGAR
20. Oct 16, 20248-K/A EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• Brio Capital Master Fund Ltd.SCHEDULE 13G/A, 4 filings Feb 4, 2022 to Jan 14, 2026²⁵

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Sigyn Therapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARSigyn Therapeutics, Inc.¹
• CIK0001642159
• Employer ID (EIN)84-4210559³
• Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; a shell company³
• Incorporated inDelaware³
• Fiscal year endsDecember 31¹
• Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus¹
• SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance¹
• Business address9190 W Olympic Blvd # 263, Beverly Hills, CA 90212¹
• Phone619-368-2000¹
• Shares outstanding1,605,377 as of Nov 14, 2025⁶
• Public float$3.6M as of Jun 30, 2024³
• AuditorKreit & Chiu CPA LLP, Los Angeles, California PCAOB ID 6651; no auditor attestation of internal control over financial reporting³
• On EDGAR sinceMay 27, 2015¹
• Filings175 in all: 8-K (49), 10-Q (31), S-1/A (11), 10-K (10), SC 13G/A (8), 424B3 (6), UPLOAD (6), 8-K/A (5)¹
  All 30 form types

  4 (4), CORRESP (4), NT 10-K (4), NT 10-Q (4), SC 13G (4), 3 (3), DEF 14C (3), POS AM (3), PRE 14C (3), D/A (2), EFFECT (2), S-1 (2), SCHEDULE 13G/A (2), 10-K/A (1), 10-Q/A (1), 15-12G (1), 4/A (1), 8-A12G (1), D (1), DEF 14A (1), PRE 14A (1), RW (1)

• Latest filingsAnnual report (10-K) Apr 15, 2025
  Quarterly report (10-Q) Nov 14, 2025
  Proxy statement (DEF 14A) Feb 23, 2017
  Latest 8-K (8-K) Feb 20, 2026

Risk factors and legal proceedings

Legal proceedings

From time to time, we may become party to litigation or other legal proceedings that we consider to be a part of the ordinary course of our business. We are not currently involved in legal proceedings that could reasonably be expected to have a material adverse effect on our business, prospects, financial condition or results of operations. We may become involved in material legal proceedings in the future. To the best of our knowledge, none of our directors, officers or affiliates is involved in a legal proceeding adverse to our business or has a material interest adverse to our business.

The opening of Item 3, Legal Proceedings.³